



# ASX Announcement

---

## CORPORATE DIRECTORY

Chairman

PAUL KRISTENSEN

Founder, Managing Director  
DAVID BUDGE

Business Development  
and Marketing Director  
NATHAN HENRY

Non-Executive Director  
MEL ASHTON

Non-Executive Director  
and Company Secretary  
MATHEW WHYTE

## Changes to Company & Director's Securities Holdings

Aurora Labs Limited ("Aurora" or "the Company") is pleased to provide the attached *Appendix 3B – New Issue Announcement* in relation to the issue of 2,945,934 fully paid ordinary shares following the receipt of **\$589,167** for the exercise of 2,945,934 unquoted options at \$0.20 each, expiring 31 December 2018 (ASX: A3DAH).

### Changes to Director's Security Holdings

Aurora also now provides an Appendix 3Y Notice for Mr Nathan Henry arising from the issue today of 993,334 shares following the exercise of 993,334 A3DAH unquoted options by Mr Henry at \$0.20 per option.

---

## FAST FACTS

Issued Capital: 74.9m

Quoted Options: 3.7m

Unquoted Options: 3.0m

Market Cap: \$38.3m

Cash: \$2.3m

For further information please contact:

[enquiries@auroralabs3D.com](mailto:enquiries@auroralabs3D.com)

---

## CONTACT DETAILS

U2/79 Bushland Ridge,  
Bibra Lake, WA  
AUSTRALIA 6163

[enquiries@auroralabs3d.com](mailto:enquiries@auroralabs3d.com)  
t. +61 (0)8 9434 1934  
[auroralabs3d.com](http://auroralabs3d.com)

---

**ASX CODE: A3D**

**ACN: 601 164 505**

For personal use only

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

Aurora Labs Limited

ABN

44 601 164 505

We (the entity) give ASX the following information.

### Part 1 - All issues

*You must complete the relevant sections (attach sheets if there is not enough space).*

- |   |   |  |
|---|---|--|
| 1 | +Class of +securities issued or to be issued  | Ordinary fully paid shares (Shares)        |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued   | 2,945,834                                  |
| 3 | Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)                    | The Shares are fully paid ordinary shares. |
| 4 | Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?<br><br>If the additional securities do not rank equally, please state:<br>• the date from which they do<br>• the extent to which they | Yes  |

For personal use only

|    |  |  |
|----|--|--|
|    | <p>participate for the next dividend, (in the case of a trust, distribution) or interest payment</p> <ul style="list-style-type: none"> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul> |  |
| 5  | Issue price or consideration   | \$589,167<br>Being 2,945,834 Shares on the exercise of 2,945,834 unquoted options expiring 31/12/2018. |
| 6  | Purpose of the issue<br>(If issued as consideration for the acquisition of assets, clearly identify those assets)  | Refer to Section 2.3 of Prospectus dated 9 June 2016.  |
| 6a | <p>Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i</p>   | Yes  |
| 6b | The date the security holder resolution under rule 7.1A was passed   | 30 November 2018   |
| 6c | Number of +securities issued without security holder approval under rule 7.1   | Not applicable   |
| 6d | Number of +securities issued with security holder approval under rule 7.1A   | Not applicable   |
| 6e | Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)  | Not applicable   |

+ See chapter 19 for defined terms.

For personal use only

|    |  |  |   |
|----|--|--|---|
| 6f | Number of securities issued under an exception in rule 7.2   | 2,945,843 Shares                         |   |
| 6g | If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation. | Not applicable.                          |   |
| 6h | If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements  | Not applicable.                          |   |
| 6i | Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements   | LR 7.1: 11,216,041<br>LR 7.1A: 7,494,027 |   |
| 7  | Dates of entering +securities into uncertificated holdings or despatch of certificates   | 24 December 2018                         |   |
| 8  | Number and +class of all +securities quoted on ASX (including the securities in section 2 if applicable)   | Number                                   | +Class  |
|    |  | 74,965,271<br>3,686,000                  | Ordinary shares<br>Options exercisable at \$1.00 & Expiry 17/4/2020         |
| 9  | Number and +class of all +securities not quoted on ASX (including the securities in section 2 if applicable)   | Number                                   | +Class  |
|    |  | 516,925                                  | Unquoted Options<br>Exercisable at \$0.20<br>Expiring 31/12/2018<br>(A3DAH) |
|    |  | 250,000                                  | Unquoted Options<br>Exercisable at \$0.50<br>Expiring 31/12/2020<br>(A3DAI) |
|    |  | 480,000                                  | Unquoted Options<br>Exercisable at \$2.23<br>Expiring 30/11/2019<br>(A3DAI) |
|    |  | 931,000                                  | Unquoted Options<br>Exercisable at \$3.00<br>Expiring 31/03/2020<br>(A3DAI) |

|           |   |
|-----------|---|
| 40,000    | Unquoted Options<br>Exercisable at \$1.17<br>Expiring 30/06/2020<br>(A3DAI) |
| 462,000   | Unquoted Options<br>Exercisable at \$0.79<br>Expiring 31/08/2020<br>(A3DAI) |
| 50,000    | Unquoted Options<br>Exercisable at \$0.72<br>Expiring 30/09/2020<br>(A3DAI) |
| 100,000   | Unquoted Options<br>Exercisable at \$0.95<br>Expiring 31/07/2020<br>(A3DAI) |
| 200,000   | Unquoted Options<br>Exercisable at \$1.08<br>Expiring 31/01/2021<br>(A3DAI) |
| 7,612,500 | Class C Performance<br>Shares (A3DAI):                                      |
| 867,159   | Performance Rights<br>expiring 31/01/2023                                   |

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) Not applicable.

## Part 2 - Bonus issue or pro rata issue

11 Is security holder approval required? Not applicable.

12 Is the issue renounceable or non-renounceable? Not applicable.

13 Ratio in which the <sup>+</sup>securities will be offered Not applicable.

14 <sup>+</sup>Class of <sup>+</sup>securities to which the offer relates Not applicable.

15 <sup>+</sup>Record date to determine entitlements Not applicable.

<sup>+</sup> See chapter 19 for defined terms.

|    |   |                 |
|----|---|-----------------|
| 16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?  | Not applicable. |
| 17 | Policy for deciding entitlements in relation to fractions   | Not applicable. |
| 18 | Names of countries in which the entity has +security holders who will not be sent new issue documents<br><br><small>Note: Security holders must be told how their entitlements are to be dealt with.<br/>Cross reference: rule 7.7.</small> | Not applicable. |
| 19 | Closing date for receipt of acceptances or renunciations  | Not applicable. |
| 20 | Names of any underwriters   | Not applicable. |
| 21 | Amount of any underwriting fee or commission  | Not applicable. |
| 22 | Names of any brokers to the issue   | Not applicable. |
| 23 | Fee or commission payable to the broker to the issue  | Not applicable. |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders   | Not applicable. |
| 25 | If the issue is contingent on +security holders' approval, the date of the meeting  | Not applicable. |
| 26 | Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled  | Not applicable. |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders   | Not applicable. |

- |    |  |                 |
|----|--|-----------------|
| 28 | Date rights trading will begin (if applicable)   | Not applicable. |
| 29 | Date rights trading will end (if applicable)   | Not applicable. |
| 30 | How do <sup>+</sup> security holders sell their entitlements <i>in full</i> through a broker?                            | Not applicable. |
| 31 | How do <sup>+</sup> security holders sell <i>part</i> of their entitlements through a broker and accept for the balance? | Not applicable. |
| 32 | How do <sup>+</sup> security holders dispose of their entitlements (except by sale through a broker)?                    | Not applicable. |
| 33 | <sup>+</sup> Despatch date   | Not applicable. |

### Part 3 - Quotation of securities

*You need only complete this section if you are applying for quotation of securities*

- 34 Type of securities  
(tick one)
- (a)  Securities described in **Part 1**
- (b)  All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

*Tick to indicate you are providing the information or documents*

- 35  If the <sup>+</sup>securities are <sup>+</sup>equity securities, the names of the 20 largest holders of the additional <sup>+</sup>securities, and the number and percentage of additional <sup>+</sup>securities

---

<sup>+</sup> See chapter 19 for defined terms.

held by those holders

- 36  If the <sup>+</sup>securities are <sup>+</sup>equity securities, a distribution schedule of the additional <sup>+</sup>securities setting out the number of holders in the categories
- 1 - 1,000
  - 1,001 - 5,000
  - 5,001 - 10,000
  - 10,001 - 100,000
  - 100,001 and over
- 37  A copy of any trust deed for the additional <sup>+</sup>securities



**Entities that have ticked box 34(b)**

38 Number of securities for which +quotation is sought Not applicable.

39 Class of +securities for which quotation is sought Not applicable.

40 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Not applicable.

41 Reason for request for quotation now Not applicable.

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

|   | Number          | +Class |
|---|-----------------|--------|
| 42 Number and +class of all +securities quoted on ASX (including the securities in clause 38) | Not applicable. |        |

+ See chapter 19 for defined terms.

For personal use only

### Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:



(Director & Company Secretary)

Date: 24 December 2018

Print name:

Mathew Whyte

== == == == ==

---

+ See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12

### Part 1

| <b>Rule 7.1 – Issues exceeding 15% of capital</b>  |  |
|--|--|
| <b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>  |  |
| <b>Insert</b> number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue   | 58,617,771   |
| <p><b>Add</b> the following:</p> <ul style="list-style-type: none"> <li>• Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>• Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> <li>• Number of partly paid ordinary securities that became fully paid in that 12 month period</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• <i>Include only ordinary securities here – other classes of equity securities cannot be added</i></li> <li>• <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul> | <ul style="list-style-type: none"> <li>• 354,500 (Shares issued on 02/03/2018)</li> <li>• 10,000 (Shares issued on 17/04/2018)</li> <li>• 245,000 (Shares issued on 12/07/2018)</li> <li>• 2,158,500 (Shares issued on 8/10/2018)</li> <li>• 880,000 (Shares issued on 31/10/2018)</li> <li>• 283,333 (Shares issued on 26/11/2018)</li> <li>• 3,073,333 (Shares issued on 12/12/2018)</li> <li>• 2,945,834 (Shares issued on 24/12/2018)</li> </ul> <p>All on exercise of Options (LR 7.2 exception 4)</p> <ul style="list-style-type: none"> <li>• 6,250,000 (Shares issued under placement on 02/03/2018 ratified at EGM held on 17/4/2018); and</li> <li>• 122,000 (Shares issued under SPP on 17/04/2018 ratified at EGM held on 17/04/2018)</li> </ul> |
| <b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month period   | Nil  |
| <b>“A”</b>   | 74,940,271   |

+ See chapter 19 for defined terms.

For personal use only

|  |  |
|--|--|
| <b>Step 2: Calculate 15% of “A”</b>  |  |
| <b>“B”</b>   | [Note: this value cannot be changed]   |
| <b>Multiply “A” by 0.15</b>  | 11,241,041   |
| <b>Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used</b>   |  |
| <p><b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> <li>• Under an exception in rule 7.2</li> <li>• Under rule 7.1A</li> <li>• With security holder approval under rule 7.1 or rule 7.4</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>• Include here (if applicable ) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>• It may be useful to set out issues of securities on different dates as separate line items</li> </ul> | •25,000 (shares issued on 30/08/2018)  |
| <b>“C”</b>   | 25,000   |
| <b>Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1</b>  |  |
| <p><b>“A” x 0.15</b></p> <p><i>Note: number must be same as shown in Step 2</i></p>  | 11,241,041   |
| <p><b>Subtract “C”</b></p> <p><i>Note: number must be same as shown in Step 3</i></p>  | 25,000   |
| <b>Total [“A” x 0.15] – “C”</b>  | <b>11,216,041</b><br>[Note: this is the remaining placement capacity under rule 7.1] |

+ See chapter 19 for defined terms.

## Part 2

| <b>Rule 7.1A – Additional placement capacity for eligible entities</b>   |   |
|--|---|
| <b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>  |   |
| <b>“A”</b><br><br><i>Note: number must be same as shown in Step 1 of Part 1</i>  | 74,940,271  |
| <b>Step 2: Calculate 10% of “A”</b>  |   |
| <b>“D”</b>   | <i>Note: this value cannot be changed</i>   |
| <b>Multiply “A” by 0.10</b>  | 7,494,027   |
| <b>Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used</b>  |   |
| <b>Insert</b> number of equity securities issued or agreed to be issued in that 12- month period under rule 7.1A<br><br><b>Notes:</b> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities – not just ordinary securities</i></li> <li>• <i>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul> | Nil   |
| <b>“E”</b>   | Nil   |
| <b>Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A</b>   |   |
| <b>“A” x 0.10</b><br><br><i>Note: number must be same as shown in Step 2</i>   | 7,494,027   |
| <b>Subtract “E”</b><br><br><i>Note: number must be same as shown in Step 3</i>   | Nil   |
| <b>Total [“A” x 0.10] – “E”</b>  | <b>7,494,027</b><br><i>Note: this is the remaining placement capacity under rule 7.1A</i> |

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|  |
|--|
| <b>Name of entity: AURORA LABS LIMITED</b> |
| <b>ABN: 44 601 164 505</b>                 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                   |
|----------------------------|-------------------|
| <b>Name of Director</b>    | John Nathan Henry |
| <b>Date of last notice</b> | 12 December 2018  |

**Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |   |
|---|---|
| <b>Direct or indirect interest</b>  | Indirect & Direct   |
| <b>Nature of indirect interest (including registered holder)</b><br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | Registered Holder: Buttes Pty Ltd <Toklat A/C><br>Relevant interest: Director   |
| <b>Date of change</b>   | 24 December 2018  |
| <b>No. of securities held prior to change</b>   | <u>Direct</u><br>1. 832,151 Ordinary Shares<br>2. 993,334 Options (Ex \$0.20/ Expiry 31/12/2018)<br>3. 185,634 Class C Performance Shares<br><br><u>Indirect</u><br>1. 150,000 Ordinary Shares<br>4. 140,000 Options (Ex \$2.23/Expiry 30/11/2019)<br>5. 125,000 Options (Ex \$3.00/Expiry 31/3/2020)<br>6. 15,000 Options (Ex \$0.79/Expiry 31/08/2020)<br>7. 50,000 Performance Rights (Exp 31/01/2023) |

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

|  |  |
|--|--|
| <b>Class</b>   | <ol style="list-style-type: none"> <li>1. Ordinary Shares</li> <li>2. Unquoted Options (Ex\$0.20/ Expiry 31/12/2018)</li> <li>3. Class C Performance Shares</li> <li>4. Unquoted Options (Ex \$2.23/Expiry 30/11/2019)</li> <li>5. Unquoted Options (Ex \$3.00/Expiry 31/3/2020)</li> <li>6. Unquoted Options (Ex \$0.79/Expiry 31/8/2020)</li> <li>7. Performance Rights (Expiry 31/1/ 2023)</li> </ol>   |
| <b>Number acquired</b>   | <ol style="list-style-type: none"> <li>1. 993,334 Ordinary Shares</li> </ol>   |
| <b>Number disposed</b>   | <ol style="list-style-type: none"> <li>2. 993,334 Options</li> </ol>   |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and estimated valuation</small>   | \$0.20 per Option  |
| <b>No. of securities held after change</b>   | <p><u>Direct</u></p> <ol style="list-style-type: none"> <li>1. 1,825,485 Ordinary Shares</li> <li>3. 185,634 Class C Performance Shares</li> </ol> <p><u>Indirect</u></p> <ol style="list-style-type: none"> <li>1. 150,000 Ordinary Shares</li> <li>4. 140,000 Options (Ex \$2.23/ Exp 30/11/2019)</li> <li>5. 125,000 Options (Ex \$3.00/Exp 31/03/2020)</li> <li>6. 15,000 Unquoted Options (Ex \$0.79/Expiry 31/08/2020)</li> <li>7. 50,000 Performance Rights (Exp 31/01/2023)</li> </ol> |
| <b>Nature of change</b><br><small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | Exercise of Options.   |

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|                           |     |
|---------------------------|-----|
| <b>Detail of contract</b> | N/A |
|---------------------------|-----|

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

|   |  |
|---|--|
| <b>Nature of interest</b>   |  |
| <b>Name of registered holder (if issued securities)</b>   |  |
| <b>Date of change</b>   |  |
| <b>No. and class of securities to which interest related prior to change</b><br><small>Note: Details are only required for a contract in relation to which the interest has changed</small> |  |
| <b>Interest acquired</b>  |  |
| <b>Interest disposed</b>  |  |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and an estimated valuation</small>   |  |
| <b>Interest after change</b>  |  |

**Part 3 – <sup>+</sup>Closed period**

|   |     |
|---|-----|
| <b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b> | No  |
| <b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>  | N/A |
| <b>If prior written clearance was provided, on what date was this provided?</b>   | N/A |

<sup>+</sup> See chapter 19 for defined terms.

For personal use only